Login to Your Account

Regeneron Completes Rolling BLA For IL-1 Trap In CAPS

By Jennifer Boggs

Monday, June 11, 2007
Hoping to introduce the first marketed product for a group of rare chronic inflammatory conditions, Regeneron Pharmaceuticals Inc. completed a rolling biologics license application for its interleukin-1 (IL-1) Trap. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription